AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10369491 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron (14 mg/d) and 260 mg/d vitamin C (Group B)
Number of subjects: 40
Study 7575897 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusions of 250 ml 10% HES 200/0.5
Number of subjects: 200
Study 7575897 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusions of 500 ml 10% HES 200/0.5
Number of subjects: 200
Study 7575897 — intervention group
Group type: COMPARATOR
Intervention: Saline infusions (previous study)
Number of subjects: 200
Study 2190502 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous fentanyl infusion
Number of subjects: 28
Study 2190502 — intervention group
Group type: COMPARATOR
Intervention: Epidural fentanyl infusion
Number of subjects: 28
Study 786694 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmefamol 1 mg
Number of subjects: 12
Study 786694 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmefamol 2 mg
Number of subjects: 12
Study 30511426 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise for 8 weeks
Number of subjects: 38
Study 30511426 — intervention group
Group type: COMPARATOR
Intervention: Non-exercise (sedentary) group
Number of subjects: 38
Study 28068987 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetyl-DL-leucine (up to 5 g per day)
Number of subjects: 108
Study 28068987 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetyl-DL-leucine
Number of subjects: 108
Study 28068987 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study 25583139 — intervention group
Group type: EXPERIMENTAL
Intervention: Favorable psychosocial factors in youth
Number of subjects: 1089
Study 25583139 — intervention group
Group type: EXPERIMENTAL
Intervention: Favorable socioeconomic environment
Number of subjects: 1089
Study 25583139 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants' self‐regulatory behavior
Number of subjects: 1089
Study 24083628 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonspecific mandibular mobilization
Number of subjects: 0
Study 24083628 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific mandibular mobilization
Number of subjects: 0
Study 24083628 — intervention group
Group type: COMPARATOR
Intervention: Facial massage therapy
Number of subjects: 0
Study 21474806 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke unit care with early supported discharge (ESD)
Number of subjects: 320
Study 21474806 — intervention group
Group type: COMPARATOR
Intervention: Ordinary stroke unit care
Number of subjects: 320
Study 19488741 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine (14 mg for smokers, 7 mg for nonsmokers)
Number of subjects: 48
Study 19488741 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 16437281 — intervention group
Group type: COMPARATOR
Intervention: Heller myotomy
Number of subjects: 43
Study 16437281 — intervention group
Group type: EXPERIMENTAL
Intervention: Heller myotomy plus Dor fundoplication
Number of subjects: 43
Study 12527540 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive/Behavioral Therapy-Alone (C/B-Alone)
Number of subjects: 63
Study 12527540 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined (C/B-Alone + Desipramine)
Number of subjects: 63
Study 10706565 — intervention group
Group type: COMPARATOR
Intervention: IFN‐alpha2b 3 MU 3 times per week for 6 months
Number of subjects: 82
Study 10706565 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron reduction before and during IFN‐alpha2b 3 MU 3 times per week for 6 months
Number of subjects: 82
Study 9345325 — intervention group
Group type: EXPERIMENTAL
Intervention: HFX/PE (Hyperfractionated radiation therapy with concurrent chemotherapy)
Number of subjects: 279
Study 9345325 — intervention group
Group type: COMPARATOR
Intervention: HFX (Hyperfractionated radiation therapy alone)
Number of subjects: 279
Study 9345325 — intervention group
Group type: EXPERIMENTAL
Intervention: HFX/PE
Number of subjects: 279
Study 9345325 — intervention group
Group type: COMPARATOR
Intervention: HFX
Number of subjects: 279
Study 8456469 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-deoxyspergualin
Number of subjects: 25
Study 8456469 — intervention group
Group type: COMPARATOR
Intervention: OKT3
Number of subjects: 25
Study 3954817 — intervention group
Group type: EXPERIMENTAL
Intervention: Drugs from 7 psychopharmacological classes
Number of subjects: 0
Study 3954817 — intervention group
Group type: EXPERIMENTAL
Intervention: Static pupillometry
Number of subjects: 0
Study 31234234 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical pharmacist intervention via home medication management review (HMMR)
Number of subjects: 158
Study 27020070 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin treatment (placebo)
Number of subjects: 77
Study 27020070 — intervention group
Group type: EXPERIMENTAL
Intervention: Serotonin treatment (placebo)
Number of subjects: 77
Study 27020070 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 77
Study 23937692 — intervention group
Group type: EXPERIMENTAL
Intervention: Gaze cues
Number of subjects: 0
Study 23937692 — intervention group
Group type: EXPERIMENTAL
Intervention: Symbolic cues
Number of subjects: 0
Study 23937692 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional connectivity analysis during gaze cueing
Number of subjects: 0
Study 22781571 — intervention group
Group type: EXPERIMENTAL
Intervention: Endo‐A‐CAB (minimally invasive technique)
Number of subjects: 194
Study 22781571 — intervention group
Group type: COMPARATOR
Intervention: sternotomy OPCAB (control group)
Number of subjects: 194
Study 22781571 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 194
Study 21092445 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intervention (coronary angiography < 24 hours after randomization)
Number of subjects: 814
Study 21092445 — intervention group
Group type: COMPARATOR
Intervention: Delayed intervention (coronary angiography > 36 hours after randomization)
Number of subjects: 814
Study 18756476 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproate
Number of subjects: 447
Study 18756476 — intervention group
Group type: COMPARATOR
Intervention: Lamotrigine
Number of subjects: 447
Study 18756476 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproate (age < 26 years)
Number of subjects: 447
Study 18756476 — intervention group
Group type: COMPARATOR
Intervention: Lamotrigine (age < 26 years)
Number of subjects: 447
Study 18756476 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproate (age ≥ 26 years)
Number of subjects: 447
Study 18756476 — intervention group
Group type: COMPARATOR
Intervention: Lamotrigine (age ≥ 26 years)
Number of subjects: 447
Study 16089270 — intervention group
Group type: EXPERIMENTAL
Intervention: Euglycemic clamp (CI)
Number of subjects: 9
Study 16089270 — intervention group
Group type: COMPARATOR
Intervention: Placebo clamp (PI)
Number of subjects: 9
Study 12091998 — intervention group
Group type: COMPARATOR
Intervention: Primary sinus surgery
Number of subjects: 40
Study 12091998 — intervention group
Group type: EXPERIMENTAL
Intervention: Revision sinus surgery
Number of subjects: 40
Study 10519625 — intervention group
Group type: EXPERIMENTAL
Intervention: One direct current electrical pulse at 1.36‐1.50 kV/cm for 40‐60 micros (group 1)
Number of subjects: 104
Study 10519625 — intervention group
Group type: EXPERIMENTAL
Intervention: Three pulses every 15‐20 minutes (group 2)
Number of subjects: 104
Study 10519625 — intervention group
Group type: COMPARATOR
Intervention: Treated the same as group 2 but with no electrical stimulation (group 3)
Number of subjects: 104
Study 8620707 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital-based outpatient pulmonary rehabilitation program (HRP)
Number of subjects: 45
Study 8620707 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-care rehabilitation program (HCRP)
Number of subjects: 45
Study 8620707 — intervention group
Group type: COMPARATOR
Intervention: No rehabilitation therapy (Control group)
Number of subjects: 45
Study 2011430 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate 5 mg twice a day
Number of subjects: 40
Study 2011430 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate 10 mg twice a day
Number of subjects: 40
Study 2011430 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate 15 mg twice a day
Number of subjects: 40
Study 2011430 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 2011430 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate to high dose of methylphenidate
Number of subjects: 40
Study 6796288 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidoflazine
Number of subjects: 36
Study 6796288 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 30053298 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sodium bicarbonate supplementation to maintain venous bicarbonate levels at 24-26 mEq/L along with standard care as per KDIGO 2012 guidelines
Number of subjects: 188
Study 30053298 — intervention group
Group type: COMPARATOR
Intervention: Control group received standard care alone
Number of subjects: 188
Study 30053298 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention arm with oral sodium bicarbonate supplementation
Number of subjects: 188
Study 29893957 — intervention group
Group type: EXPERIMENTAL
Intervention: Preemptive cidofovir
Number of subjects: 572
Study 29893957 — intervention group
Group type: COMPARATOR
Intervention: Allogeneic HCT recipients with HAdV infection
Number of subjects: 572
Study 27779764 — intervention group
Group type: EXPERIMENTAL
Intervention: SF-36 Physical Function
Number of subjects: 137
Study 27779764 — intervention group
Group type: EXPERIMENTAL
Intervention: SF-36 Role Physical
Number of subjects: 137
Study 27779764 — intervention group
Group type: EXPERIMENTAL
Intervention: SF-36 Bodily Pain
Number of subjects: 137
Study 27779764 — intervention group
Group type: EXPERIMENTAL
Intervention: SF-36 Physical Component Summary
Number of subjects: 137
Study 27779764 — intervention group
Group type: EXPERIMENTAL
Intervention: SF-36 Mental Health
Number of subjects: 137
Study 27779764 — intervention group
Group type: EXPERIMENTAL
Intervention: SF-36 Mental Component Summary
Number of subjects: 137
Study 27779764 — intervention group
Group type: EXPERIMENTAL
Intervention: HADS anxiety score
Number of subjects: 137
Study 27779764 — intervention group
Group type: EXPERIMENTAL
Intervention: HADS depression score
Number of subjects: 137
Study 25557016 — intervention group
Group type: EXPERIMENTAL
Intervention: LL group (full left-lateral position)
Number of subjects: 99
Study 25557016 — intervention group
Group type: EXPERIMENTAL
Intervention: LS group (initially full left-lateral, then left-tilt supine)
Number of subjects: 99
Study 25557016 — intervention group
Group type: EXPERIMENTAL
Intervention: CS group (initially full left-lateral, then left-tilt supine with needle oriented cephalad)
Number of subjects: 99
Study 23218506 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-Rich-Fibrin (PRF)
Number of subjects: 6
Study 23218506 — intervention group
Group type: COMPARATOR
Intervention: Conventional collagen membrane (Bio-Gide(®))
Number of subjects: 6
Study 21812968 — intervention group
Group type: EXPERIMENTAL
Intervention: Edinburgh Postnatal Depression Scale (EPDS)
Number of subjects: 4150
Study 21812968 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomised trial (n = 253)
Number of subjects: 4150
Study 21812968 — intervention group
Group type: EXPERIMENTAL
Intervention: EPDS question 10 endorsement
Number of subjects: 4150
Study 21812968 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up at 18 weeks
Number of subjects: 4150
Study 19538185 — intervention group
Group type: EXPERIMENTAL
Intervention: UVB irradiation with a suberythematogenic regimen
Number of subjects: 77
Study 19538185 — intervention group
Group type: COMPARATOR
Intervention: UVB irradiation with an erythematogenic regimen
Number of subjects: 77
Study 15861492 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture on anti-smoking acupoints of the ear (case group)
Number of subjects: 238
Study 15861492 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture at other sites of the ear (control group)
Number of subjects: 238
Study 15916412 — intervention group
Group type: EXPERIMENTAL
Intervention: Glasgow Outcome Scale (GOS)
Number of subjects: 0
Study 15916412 — intervention group
Group type: EXPERIMENTAL
Intervention: Eight-point expanded scale
Number of subjects: 0
Study 15916412 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropsychological tests
Number of subjects: 0
Study 15916412 — intervention group
Group type: EXPERIMENTAL
Intervention: Surrogate outcome measures (magnetic resonance imaging, neurochemical, neuropsychological, quality of life measures)
Number of subjects: 0
Study 10621984 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice-based educational visits encouraging exploration of barriers to change
Number of subjects: 18
Study 10621984 — intervention group
Group type: COMPARATOR
Intervention: Control group (no encouragement to explore barriers)
Number of subjects: 18
Study 8610232 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinorelbine (single agent)
Number of subjects: 0
Study 8610232 — intervention group
Group type: COMPARATOR
Intervention: Vindesine/Cisplatin (combination)
Number of subjects: 0
Study 8610232 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinorelbine/Cisplatin (combination)
Number of subjects: 0
Study 8610232 — intervention group
Group type: COMPARATOR
Intervention: 5-Fluorouracil and Leucovorin (control)
Number of subjects: 0
Study 1821699 — intervention group
Group type: EXPERIMENTAL
Intervention: Total sleep deprivation (TSD)
Number of subjects: 0
Study 7044797 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin 50 mg t.i.d.
Number of subjects: 40
Study 7044797 — intervention group
Group type: EXPERIMENTAL
Intervention: Benoxaprofen 600 mg once daily
Number of subjects: 40
Study 7044797 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin
Number of subjects: 40
Study 7044797 — intervention group
Group type: COMPARATOR
Intervention: Benoxaprofen
Number of subjects: 40
Study 31668476 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time functional magnetic resonance imaging neurofeedback from the SMA
Number of subjects: 21
Study 31668476 — intervention group
Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 21
Study 30842118 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-traumatic stress disorder (PTSD)
Number of subjects: 1032
Study 29084790 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led intervention with tailored telephone consultations, varying in intensity and follow-up frequency.
Number of subjects: 6000
Study 25483598 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide transnasal nebulization
Number of subjects: 60
Study 25483598 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 23983157 — intervention group
Group type: COMPARATOR
Intervention: Traditional retention strategy - mailed reminder letters (referent category)
Number of subjects: 422
Study 23983157 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional retention strategy - telephone number redials
Number of subjects: 422
Study 23983157 — intervention group
Group type: EXPERIMENTAL
Intervention: Nontraditional retention strategy - Facebook outreach
Number of subjects: 422
Study 23983157 — intervention group
Group type: EXPERIMENTAL
Intervention: Nontraditional retention strategy - school administration assistance
Number of subjects: 422
Study 21852503 — intervention group
Group type: EXPERIMENTAL
Intervention: My Teaching Partner‐Secondary; a Web‐mediated approach focused on improving teacher-student interactions.
Number of subjects: 2237
Study 20068404 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Number of subjects: 0
Study 17601444 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac 0.4% (Acular LS)
Number of subjects: 132
Study 17601444 — intervention group
Group type: COMPARATOR
Intervention: Nepafenac 0.1% (Nevanac)
Number of subjects: 132
Study 15226663 — intervention group
Group type: EXPERIMENTAL
Intervention: e-AGV group (AGV implant surgery using pericardial membrane)
Number of subjects: 20
Study 15226663 — intervention group
Group type: COMPARATOR
Intervention: AGV group (AGV implant surgery without surface area extension)
Number of subjects: 20
Study 15226663 — intervention group
Group type: EXPERIMENTAL
Intervention: e-AGV group
Number of subjects: 20
Study 15226663 — intervention group
Group type: COMPARATOR
Intervention: AGV group
Number of subjects: 20
Study 12190806 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (NS) 2 ml i.v.
Number of subjects: 180
Study 12190806 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac 10 mg in 2 ml NS with venous occlusion (VO) for 30 s
Number of subjects: 180
Study 12190806 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac 10 mg in 2 ml NS with venous occlusion (VO) for 60 s
Number of subjects: 180
Study 12190806 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac 10 mg in 2 ml NS with venous occlusion (VO) for 120 s
Number of subjects: 180
Study 12190806 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac 15 mg in 2 ml NS with propofol injection after 60 s
Number of subjects: 180
Study 12190806 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac 30 mg in 2 ml NS with propofol injection after 60 s
Number of subjects: 180
Study 9694611 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (TAM) 20 mg/day for 2 years (postmenopausal)
Number of subjects: 1579
Study 9694611 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (MMC + CPA)
Number of subjects: 1579
Study 9694611 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoendocrine therapy (TAM + MMC + CPA)
Number of subjects: 1579
Study 9694611 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen (TAM)
Number of subjects: 1579
Study 7653695 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium lactate infusion
Number of subjects: 20
Study 7653695 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 20
Study 2527044 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (2.5 to 10.0 mg/d) in combination with HCTZ (50 mg/d)
Number of subjects: 20
Study 2527044 — intervention group
Group type: COMPARATOR
Intervention: HCTZ (50 mg/d) with placebo
Number of subjects: 20
Study 799977 — intervention group
Group type: EXPERIMENTAL
Intervention: Burinex K
Number of subjects: 60
Study 799977 — intervention group
Group type: COMPARATOR
Intervention: Lasix+K
Number of subjects: 60
Study 31802278 — intervention group
Group type: EXPERIMENTAL
Intervention: Irrigation fluid at body temperature (37 °C, BT-group)
Number of subjects: 172
Study 31802278 — intervention group
Group type: COMPARATOR
Intervention: Irrigation fluid at room temperature (22 °C, RT-group)
Number of subjects: 172
Study 31267613 — intervention group
Group type: EXPERIMENTAL
Intervention: MAMIR
Number of subjects: 60
Study 28536206 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg/kg dextrose gel
Number of subjects: 211
Study 28536206 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 211
Study 25984891 — intervention group
Group type: EXPERIMENTAL
Intervention: LBPP treadmill
Number of subjects: 11
Study 25984891 — intervention group
Group type: COMPARATOR
Intervention: Control treadmill
Number of subjects: 11
Study 23908163 — intervention group
Group type: EXPERIMENTAL
Intervention: ADD (feed additives including chelated minerals, organic Se, yeast culture, direct-fed microbials, and Yucca schidigera extract)
Number of subjects: 20
Study 23908163 — intervention group
Group type: EXPERIMENTAL
Intervention: ADD
Number of subjects: 20
Study 23908163 — intervention group
Group type: COMPARATOR
Intervention: CTRL (control group without additives)
Number of subjects: 20
Study 23908163 — intervention group
Group type: COMPARATOR
Intervention: CTRL
Number of subjects: 20
Study 21571345 — intervention group
Group type: EXPERIMENTAL
Intervention: Silodosin 4 mg
Number of subjects: 151
Study 21571345 — intervention group
Group type: EXPERIMENTAL
Intervention: Silodosin 8 mg
Number of subjects: 151
Study 21571345 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study 17999976 — intervention group
Group type: EXPERIMENTAL
Intervention: Single intravenous dose of 600 mg linezolid
Number of subjects: 24
Study 17999976 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-daily administration of linezolid (extrapolated)
Number of subjects: 24
Study 17999976 — intervention group
Group type: COMPARATOR
Intervention: Control group (historic data from healthy volunteers)
Number of subjects: 24
Study 15713524 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine 1000 mg/m2 on days 1, 8, 15, every 28 days (arm Q4W)
Number of subjects: 81
Study 15713524 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine 1125 mg/m2 on days 1 and 8, every 21 days (arm Q3W)
Number of subjects: 81
Study 11943073 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg diclofenac sodium
Number of subjects: 12
Study 11943073 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 9794735 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacidipine (calcium antagonist)
Number of subjects: 2259
Study 9794735 — intervention group
Group type: COMPARATOR
Intervention: Atenolol (beta-blocker)
Number of subjects: 2259
Study 9097789 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate prophylactic panretinal photocoagulation (PRP)
Number of subjects: 181
Study 9097789 — intervention group
Group type: COMPARATOR
Intervention: Close observation (control group)
Number of subjects: 181
Study 9097789 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP treatment after TC‐INV/ANV developed
Number of subjects: 181
Study 9097789 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP treatment after TC‐INV/ANV developed (previously treated eyes)
Number of subjects: 181
Study 2669938 — intervention group
Group type: COMPARATOR
Intervention: Bromovinyldeoxyuridine (BVDU) + placebo
Number of subjects: 22
Study 2669938 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromovinyldeoxyuridine (BVDU) + 1.5 X 10(6) IU recombinant a 2C interferon
Number of subjects: 22
Study 31512365 — intervention group
Group type: EXPERIMENTAL
Intervention: metformin plus lifestyle intervention (LSI)
Number of subjects: 0
Study 31512365 — intervention group
Group type: COMPARATOR
Intervention: lifestyle intervention (LSI)
Number of subjects: 0
Study 31512365 — intervention group
Group type: EXPERIMENTAL
Intervention: metformin 850 mg once daily for the first 2 weeks, then twice daily thereafter
Number of subjects: 0
Study 29362047 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.2 mcg/kg/hour)
Number of subjects: 82